110 related articles for article (PubMed ID: 8218996)
1. Immunohistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis.
Lee CS; Rush M; Charalambous D; Rode J
J Gastroenterol Hepatol; 1993; 8(5):465-9. PubMed ID: 8218996
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
3. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of heat shock protein (hsp) 70 associated with abnormal p53 expression in cancer of the pancreas.
Lee CS; Montebello J; Rush M; Georgiou T; Wawryk S; Rode J
Zentralbl Pathol; 1994 Aug; 140(3):259-64. PubMed ID: 7947633
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking.
Lee EU; Cibull ML; O'Daniel-Pierce E; Strodel WE; Jennings CD
Int J Pancreatol; 1995 Jun; 17(3):237-42. PubMed ID: 7642971
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis.
Casey G; Yamanaka Y; Friess H; Kobrin MS; Lopez ME; Buchler M; Beger HG; Korc M
Cancer Lett; 1993 May; 69(3):151-60. PubMed ID: 8513440
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 tumor suppressor gene, oncoprotein c-erbB-2, cellular proliferation and differentiation in malignant and benign pancreatic lesions.
Jaskiewicz K; Krige JE; Thomson J
Anticancer Res; 1994; 14(5A):1919-22. PubMed ID: 7847827
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma.
Ishimaru S; Itoh M; Hanada K; Tsuchida A; Iwao T; Kajiyama G
Cancer; 1996 Jun; 77(11):2233-9. PubMed ID: 8635089
[TBL] [Abstract][Full Text] [Related]
9. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.
Lüttges J; Diederichs A; Menke MA; Vogel I; Kremer B; Klöppel G
Cancer; 2000 Jun; 88(11):2495-504. PubMed ID: 10861425
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.
van Es JM; Polak MM; van den Berg FM; Ramsoekh TB; Craanen ME; Hruban RH; Offerhaus GJ
J Clin Pathol; 1995 Mar; 48(3):218-22. PubMed ID: 7730480
[TBL] [Abstract][Full Text] [Related]
11. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Jeong S; Lee DH; Lee JI; Lee JW; Kwon KS; Kim PS; Kim HG; Shin YW; Kim YS; Kim YB
World J Gastroenterol; 2005 Nov; 11(43):6765-9. PubMed ID: 16425381
[TBL] [Abstract][Full Text] [Related]
12. Lack of p53 immunoreactivity in pancreatic endocrine tumors.
Lee CS
Pathology; 1996 May; 28(2):139-41. PubMed ID: 8743819
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Barton CM; Staddon SL; Hughes CM; Hall PA; O'Sullivan C; Klöppel G; Theis B; Russell RC; Neoptolemos J; Williamson RC
Br J Cancer; 1991 Dec; 64(6):1076-82. PubMed ID: 1764370
[TBL] [Abstract][Full Text] [Related]
14. p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells.
Bartz C; Ziske C; Wiedenmann B; Moelling K
Gut; 1996 Mar; 38(3):403-9. PubMed ID: 8675094
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.
Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M
Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
17. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
Yantiss RK; Woda BA; Fanger GR; Kalos M; Whalen GF; Tada H; Andersen DK; Rock KL; Dresser K
Am J Surg Pathol; 2005 Feb; 29(2):188-95. PubMed ID: 15644775
[TBL] [Abstract][Full Text] [Related]
18. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer.
Lundin J; Nordling S; von Boguslawsky K; Roberts PJ; Haglund C
Oncology; 1996; 53(2):104-11. PubMed ID: 8604235
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 protein during pancreatitis.
Maacke H; Kessler A; Schmiegel W; Roeder C; Vogel I; Deppert W; Kalthoff H
Br J Cancer; 1997; 75(10):1501-4. PubMed ID: 9166944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
